Oncolytics Biotech Inc ONCY

Pfizer’s bispecific approved for relapsed or refractory MM

[Noteable]

The FDA on Monday granted accelerated approval to Pfizer’s bispecific antibody elranatamab, to be marketed as Elrexfio, for the treatment of relapsed or refractory multiple myeloma.

Monday’s approval makes Elrexfio the first off-the-shelf, ready-to-use fixed-dose subcutaneous therapeutic that targets the BCMA protein.

https://www.biospace.com/article/pfizer-bispecific-drug-wins-fda-accelerated-approval-for-multiple-myeloma/

[Noteable]

ELREXFIO is a subcutaneously delivered B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody (BsAb) immunotherapy that binds to BCMA on myeloma cells and CD3 on T-cells, bringing them together and activating the T-cells to kill myeloma cells. https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-inc?threadid=34957252 https://stockhouse.com/companies/bullboard/oncy

[Noteable]

 - Dont forget this -